Boehringer Ingelheim Tipranavir NDA Could Signal Novel HIV Salvage Option
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Boehringer Ingelheim is seeking a claim for its newly filed AIDS therapy tipranavir as a treatment for multi-drug-resistant HIV patients.